↓ Skip to main content

Michigan Publishing

Article Metrics

Dusquetide: Reduction in Oral Mucositis associated with Enduring Ancillary Benefits in Tumor Resolution and Decreased Mortality in Head and Neck Cancer Patients

Overview of attention for article published in Biotechnology Reports, May 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 123)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
62 news outlets
twitter
1 tweeter

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
14 Mendeley
Title
Dusquetide: Reduction in Oral Mucositis associated with Enduring Ancillary Benefits in Tumor Resolution and Decreased Mortality in Head and Neck Cancer Patients
Published in
Biotechnology Reports, May 2017
DOI 10.1016/j.btre.2017.05.002
Pubmed ID
Authors

Kudrimoti, Mahesh, Curtis, Amarinthia, Azawi, Samar, Worden, Francis, Katz, Sanford, Adkins, Douglas, Bonomi, Marcelo, Scott, Zack, Elder, Jenna, Sonis, Stephen T., Straube, Richard, Donini, Oreola, Mahesh Kudrimoti, Amarinthia Curtis, Samar Azawi, Francis Worden, Sanford Katz, Douglas Adkins, Marcelo Bonomi, Zack Scott, Jenna Elder, Stephen T. Sonis, Richard Straube, Oreola Donini

Abstract

Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 4 29%
Student > Master 3 21%
Researcher 2 14%
Student > Bachelor 2 14%
Other 1 7%
Other 2 14%
Readers by discipline Count As %
Medicine and Dentistry 5 36%
Unspecified 4 29%
Biochemistry, Genetics and Molecular Biology 2 14%
Agricultural and Biological Sciences 1 7%
Social Sciences 1 7%
Other 1 7%

Attention Score in Context

This research output has an Altmetric Attention Score of 485. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2018.
All research outputs
#14,479
of 12,293,384 outputs
Outputs from Biotechnology Reports
#1
of 123 outputs
Outputs of similar age
#827
of 267,790 outputs
Outputs of similar age from Biotechnology Reports
#1
of 12 outputs
Altmetric has tracked 12,293,384 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 123 research outputs from this source. They receive a mean Attention Score of 1.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,790 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.